- Home
- CSTL vs TMP Comparison
CSTL vs TMP Comparison
Compare CSTL & TMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TMP
- Stock Information
- Founded
- CSTL 2007
- TMP 1836
- Country
- CSTL United States
- TMP United States
- Employees
- CSTL N/A
- TMP N/A
- Industry
- CSTL Medical Specialities
- TMP Major Banks
- Sector
- CSTL Health Care
- TMP Finance
- Exchange
- CSTL Nasdaq
- TMP Nasdaq
- Market Cap
- CSTL 456.2M
- TMP 878.2M
- IPO Year
- CSTL 2019
- TMP N/A
- Fundamental
- Price
- CSTL $20.30
- TMP $66.66
- Analyst Decision
- CSTL Strong Buy
- TMP Buy
- Analyst Count
- CSTL 6
- TMP 2
- Target Price
- CSTL $37.67
- TMP $69.00
- AVG Volume (30 Days)
- CSTL 451.0K
- TMP 52.6K
- Earning Date
- CSTL 08-04-2025
- TMP 07-25-2025
- Dividend Yield
- CSTL N/A
- TMP 3.72%
- EPS Growth
- CSTL N/A
- TMP 980.13
- EPS
- CSTL N/A
- TMP 5.16
- Revenue
- CSTL $347,083,000.00
- TMP $297,067,000.00
- Revenue This Year
- CSTL N/A
- TMP $13.79
- Revenue Next Year
- CSTL $1.36
- TMP $6.90
- P/E Ratio
- CSTL N/A
- TMP $12.92
- Revenue Growth
- CSTL 38.43
- TMP 40.19
- 52 Week Low
- CSTL $15.45
- TMP $46.19
- 52 Week High
- CSTL $35.84
- TMP $79.01
- Technical
- Relative Strength Index (RSI)
- CSTL 66.43
- TMP 67.23
- Support Level
- CSTL $20.00
- TMP $62.37
- Resistance Level
- CSTL $20.63
- TMP $64.07
- Average True Range (ATR)
- CSTL 0.76
- TMP 1.45
- MACD
- CSTL 0.16
- TMP 0.51
- Stochastic Oscillator
- CSTL 88.88
- TMP 98.66
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.